DIX; Daniel

Patent Applications and Registrations

Patent applications and USPTO patent grants for DIX; Daniel.The latest application filed is for "vegf antagonist formulations suitable for intravitreal administration".

Company Profile

10.31.36

DIX; Daniel - LaGrangeville NY
Dix; Daniel - Tarrytown NY
- LaGrangeville NY US
Dix; Daniel - Irvine CA
Dix; Daniel - Langrangeville NY

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Vegf Antagonist Formulations Suitable For Intravitreal Administration App 20210340220 - FURFINE; Eric ; et al.	2021-11-04
VEGF antagonist formulations suitable for intravitreal administration Grant 11,084,865 - Furfine , et al. August 10, 2	2021-08-10
Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab Grant 11,071,780 - Vitti , et al. July 27, 2	2021-07-27
VEGF antagonist formulations suitable for intravitreal administration Grant 11,066,458 - Furfine , et al. July 20, 2	2021-07-20
Stabilized Formulations Containing Anti-NGF Antibodies App 20210107974 - Walsh; Scott ; et al.	2021-04-15
Vegf Antagonist Formulations Suitable For Intravitreal Administration App 20200131246 - FURFINE; Eric ; et al.	2020-04-30
Vegf Antagonist Formulations Suitable For Intravitreal Administration App 20200017572 - FURFINE; Eric ; et al.	2020-01-16
VEGF antagonist formulations suitable for intravitreal administration Grant 10,464,992 - Furfine , et al. No	2019-11-05
VEGF antagonist formulations suitable for intravitreal administration Grant 10,400,025 - Furfine , et al. Sep	2019-09-03
Process For Reducing Subvisible Particles In A Pharmaceutical Formulation App 20190231877 - BAK; Hanne ; et al.	2019-08-01
Process for reducing subvisible particles in a pharmaceutical formulation Grant 10,342,876 - Bak , et al. July 9, 2	2019-07-09
Methods And Formulations For Treating Vascular Eye Diseases App 20190117767 - VITTI; Robert L. ; et al.	2019-04-25
Vegf Antagonist Formulations Suitable For Intravitreal Administration App 20190031735 - FURFINE; Eric ; et al.	2019-01-31
Stabilized Formulations Containing Anti-ngf Antibodies App 20190010222 - Walsh; Scott ; et al.	2019-01-10
Vegf Antagonist Formulations Suitable For Intravitreal Administration App 20180155408 - FURFINE; Eric ; et al.	2018-06-07
VEGF antagonist formulations suitable for intravitreal administration Grant 9,914,763 - Furfine , et al. March 13, 2	2018-03-13
Stabilized formulations containing anti-DLL4 antibodies Grant 9,675,692 - Walsh , et al. June 13, 2	2017-06-13
Methods And Formulations For Treating Vascular Eye Diseases App 20170080086 - VITTI; Robert L. ; et al.	2017-03-23
Stable VEGF antagonist formulations Grant 9,511,140 - Dix , et al. December 6, 2	2016-12-06
Stable liquid formulations of dimer VEGF antagonists Grant 9,416,167 - Dix , et al. August 16, 2	2016-08-16
Vegf Antagonist Formulations Suitable For Intravitreal Administration App 20160213608 - FURFINE; Eric ; et al.	2016-07-28
Vegf Antagonist Formulations App 20160175439 - DIX; Daniel ; et al.	2016-06-23
Methods And Formulations For Treating Vascular Eye Diseases App 20160144025 - VITTI; Robert L. ; et al.	2016-05-26
VEGF antagonist formulations for intravitreal administration Grant 9,340,594 - Furfine , et al. May 17, 2	2016-05-17
Process For Reducing Subvisible Particles In A Pharmaceutical Formulation App 20160101181 - BAK; Hanne ; et al.	2016-04-14
Stabilized Formulations Containing Anti-ngf Antibodies App 20160017029 - WALSH; Scott ; et al.	2016-01-21
Vegf Antagonist Formulations App 20150079087 - DIX; Daniel ; et al.	2015-03-19
Stable liquid VEGF antagonist formulations Grant 08921316 -	2014-12-30
Stable liquid VEGF antagonist formulations Grant 8,921,316 - Dix , et al. December 30, 2	2014-12-30
VEGF Antagonist Formulations for Intravitreal Administration App 20140323983 - FURFINE; Eric ; et al.	2014-10-30
VEGF antagonist formulations for intravitreal administration Grant 8,802,107 - Furfine , et al. August 12, 2	2014-08-12
Stabilized formulations containing anti-PCSK9 antibodies Grant 8,795,669 - Walsh , et al. August 5, 2	2014-08-05
Stable liquid VEGF antagonist formulations Grant 8,710,004 - Dix , et al. April 29, 2	2014-04-29
LED universal recessed light fixture Grant 8,696,158 - Santiago , et al. April 15, 2	2014-04-15
Stabilized Formulations Containing Anti-dll4 Antibodies App 20130323260 - Walsh; Scott ; et al.	2013-12-05
VEGF Antagonist Formulations for Intravitreal Administration App 20130274189 - FURFINE; Eric ; et al.	2013-10-17
Vegf Antagonist Formulations App 20130261056 - DIX; Daniel ; et al.	2013-10-03
Stabilized Formulations Containing Anti-PCSK9 Antibodies App 20130189277 - WALSH; Scott ; et al.	2013-07-25
VEGF antagonist formulations for intravitreal administration Grant 8,481,046 - Furfine , et al. July 9, 2	2013-07-09
Dimer VEGF antagonist formulations Grant 8,404,638 - Dix , et al. March 26, 2	2013-03-26
Led Universal Recessed Light Fixture App 20120182744 - Santiago; Dwight David ; et al.	2012-07-19
Vegf Antagonist Formulations App 20120178683 - DIX; Daniel ; et al.	2012-07-12
VEGF Antagonist Formulations App 20120101035 - Dix; Daniel ; et al.	2012-04-26
VEGF Antagonist Formulations for Intravitreal Administration App 20120087929 - FURFINE; Eric ; et al.	2012-04-12
VEGF antagonist formulations Grant 8,110,546 - Dix , et al. February 7, 2	2012-02-07
Stabilized Formulations Containing Anti-ngf Antibodies App 20120014968 - Walsh; Scott ; et al.	2012-01-19
VEGF antagonist formulations for intravitreal administration Grant 8,092,803 - Furfine , et al. January 10, 2	2012-01-10
Vegf Antagonist Formulations For Intravitreal Administration App 20110257601 - FURFINE; Eric ; et al.	2011-10-20
Vegf Antagonist Formulations App 20100279933 - DIX; DANIEL ; et al.	2010-11-04
Lyophilized VEGF antagonist formulations for intravitreal administration Grant 7,807,164 - Furfine , et al. October 5, 2	2010-10-05
Lighting fixture with recessed baffle trim unit Grant 7,722,227 - Zhang , et al. May 25, 2	2010-05-25
Lyophilized VEGF Antagonist Formulations for Intravitreal Administration App 20100075903 - FURFINE; Eric ; et al.	2010-03-25
Stable liquid IL-1 antagonist formulations Grant 7,655,758 - Dix , et al. February 2, 2	2010-02-02
VEGF antagonist formulations suitable for intravitreal administration Grant 7,608,261 - Furfine , et al. October 27, 2	2009-10-27
IL-1 antagonist formulations Grant 7,572,893 - Dix , et al. August 11, 2	2009-08-11
Lighting Fixture With Recessed Baffle Trim Unit App 20090097262 - Zhang; Kanghong ; et al.	2009-04-16
Stable Liquid IL-1 Antagonist Formulations App 20080188817 - Dix; Daniel ; et al.	2008-08-07
IL-1 antagonist formulations Grant 7,365,165 - Dix , et al. April 29, 2	2008-04-29
IL-1 Antagonist Formulations App 20080015148 - Dix; Daniel ; et al.	2008-01-17
VEGF antagonist formulations suitable for intravitreal administration App 20070293432 - Furfine; Eric ; et al.	2007-12-20
VEGF antagonist formulations App 20060217311 - Dix; Daniel ; et al.	2006-09-28
IL-1 antagonist formulations App 20060040852 - Dix; Daniel ; et al.	2006-02-23